Purchase this article with an account.
D. Moreno-Paramo, G. Alvarez-Rivera, M. Abraham- Marín, N. Salazar-Terán, M. A. Martínez-Castellanos, E. Romo-García, M. Hernández-Rojas, J. L. Guerrero-Naranjo, J. Fromow-Guerra, H. Quiroz-Mercado; Intravitreal Bevacizumab (Avastin) as Treatment for Macular Edema in Vein Occlusions. Preliminary Results of a Prospective Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):309.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Evaluate visual results and changes in macular thickness measured by optical coherence tomography (OCT) in patients diagnosed with macular edema secondary to vein occlusions, treated with intravitreal Bevacizumab.
Retrospective pilot study.15 eyes diagnosed with vein occlusion , 11 with branch vein occlusions (BVO) and 4 with central retinal vein occlusion (CRVO), were treated with 1ml (1.25mg) intravitreal bevacizumab and followed up during 3 months with best-corrected visual acuity, OCT, and fluorescein angiography.
Best-corrected visual acuity mean at baseline was 20/400 which improve to 20/100 during the first month and 20/60 on the third month follow up (p=0.001, Wilcoxon Signed Rank Test). Baseline macular thickness mean was 334.60+ 145.28µm which decreased to 223.40+ 110.89µm (p=0.007, Wilcoxon Signed Rank Test) after the first month. There were no ocular or systemic adverse events identified
Intravitreal bevacizumab is a safe and effective therapy for patients with vein occlusions. The three month follow-up showed a statistically significant improvement in visual acuity, OCT, and angiographic outcomes.
This PDF is available to Subscribers Only